Umer Raffat
Stock Analyst at Evercore ISI Group
(1.67)
# 1,801
Out of 4,479 analysts
19
Total ratings
50%
Success rate
-9.16%
Average return
Main Sectors:
17 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AMLX Amylyx Pharmaceuticals | Downgrades: In-Line | n/a | $1.88 | - | 2 | Mar 8, 2024 | |
| GUTS Fractyl Health | Initiates: Outperform | n/a | $4.46 | - | 1 | Feb 28, 2024 | |
| RAPT RAPT Therapeutics | Initiates: Outperform | n/a | $2.88 | - | 1 | Feb 16, 2024 | |
| ALKS Alkermes | Upgrades: Outperform | n/a | $24.39 | - | 1 | Oct 24, 2023 | |
| CNTA Centessa Pharmaceuticals | Initiates: Outperform | n/a | $8.80 | - | 1 | Jun 21, 2023 | |
| TEVA Teva Pharmaceutical | Upgrades: Outperform | n/a | $16.34 | - | 1 | May 18, 2023 | |
| PHAT Phathom Pharmaceuticals | Upgrades: Outperform | n/a | $10.81 | - | 2 | May 11, 2023 | |
| MLYS Mineralys Therapeutics | Initiates: Outperform | n/a | $12.17 | - | 1 | Mar 7, 2023 | |
| LEGN Legend Biotech | Initiates: Outperform | n/a | $46.02 | - | 1 | Nov 2, 2022 | |
| CERE Cerevel Therapeutics Holdings | Initiates: Outperform | n/a | $41.35 | - | 1 | Sep 13, 2022 | |
| OGN Organon & Co. | Initiates: Outperform | n/a | $20.31 | - | 1 | Jun 10, 2021 | |
| KOD Kodiak Sciences | Initiates: Outperform | n/a | $2.37 | - | 1 | Mar 12, 2021 | |
| VOR Vor Biopharma | Initiates: Outperform | n/a | $0.99 | - | 1 | Mar 3, 2021 | |
| AMGN Amgen | Upgrades: Outperform | n/a | $311.01 | - | 1 | Jan 21, 2020 | |
| PIRS Pieris Pharmaceuticals | Initiates: Outperform | $1,040 | $9.70 | +10,621.65% | 1 | Mar 19, 2018 | |
| DERM Journey Medical | Initiates: Outperform | n/a | $5.37 | - | 1 | Jun 30, 2017 | |
| JAZZ Jazz Pharmaceuticals | Initiates: Buy | n/a | $106.47 | - | 1 | Feb 23, 2017 |
Amylyx Pharmaceuticals
Mar 8, 2024
Downgrades: In-Line
Price Target: n/a
Current: $1.88
Upside: -
Fractyl Health
Feb 28, 2024
Initiates: Outperform
Price Target: n/a
Current: $4.46
Upside: -
RAPT Therapeutics
Feb 16, 2024
Initiates: Outperform
Price Target: n/a
Current: $2.88
Upside: -
Alkermes
Oct 24, 2023
Upgrades: Outperform
Price Target: n/a
Current: $24.39
Upside: -
Centessa Pharmaceuticals
Jun 21, 2023
Initiates: Outperform
Price Target: n/a
Current: $8.80
Upside: -
Teva Pharmaceutical
May 18, 2023
Upgrades: Outperform
Price Target: n/a
Current: $16.34
Upside: -
Phathom Pharmaceuticals
May 11, 2023
Upgrades: Outperform
Price Target: n/a
Current: $10.81
Upside: -
Mineralys Therapeutics
Mar 7, 2023
Initiates: Outperform
Price Target: n/a
Current: $12.17
Upside: -
Legend Biotech
Nov 2, 2022
Initiates: Outperform
Price Target: n/a
Current: $46.02
Upside: -
Cerevel Therapeutics Holdings
Sep 13, 2022
Initiates: Outperform
Price Target: n/a
Current: $41.35
Upside: -
Organon & Co.
Jun 10, 2021
Initiates: Outperform
Price Target: n/a
Current: $20.31
Upside: -
Kodiak Sciences
Mar 12, 2021
Initiates: Outperform
Price Target: n/a
Current: $2.37
Upside: -
Vor Biopharma
Mar 3, 2021
Initiates: Outperform
Price Target: n/a
Current: $0.99
Upside: -
Amgen
Jan 21, 2020
Upgrades: Outperform
Price Target: n/a
Current: $311.01
Upside: -
Pieris Pharmaceuticals
Mar 19, 2018
Initiates: Outperform
Price Target: $1,040
Current: $9.70
Upside: +10,621.65%
Journey Medical
Jun 30, 2017
Initiates: Outperform
Price Target: n/a
Current: $5.37
Upside: -
Jazz Pharmaceuticals
Feb 23, 2017
Initiates: Buy
Price Target: n/a
Current: $106.47
Upside: -